首页 | 本学科首页   官方微博 | 高级检索  
     

肿瘤疫苗与白介素-12联合免疫治疗小鼠肉瘤的研究
引用本文:崔雪梅,袁玫,宋舸,睢翔,赵斌,卢世璧. 肿瘤疫苗与白介素-12联合免疫治疗小鼠肉瘤的研究[J]. 中华肿瘤防治杂志, 2007, 14(6): 415-417
作者姓名:崔雪梅  袁玫  宋舸  睢翔  赵斌  卢世璧
作者单位:解放军总医院骨科研究所,北京,100853;解放军总医院骨科研究所,北京,100853;解放军总医院骨科研究所,北京,100853;解放军总医院骨科研究所,北京,100853;解放军总医院骨科研究所,北京,100853;解放军总医院骨科研究所,北京,100853
摘    要:目的:探讨混合热休克蛋白(HSP)/肽与白介素-12(IL-12)和环磷酰胺(CTX)联合治疗小鼠肉瘤的作用及机制。方法:以S-180肉瘤为模型,将瘤组织剪碎,裂解,离心,取上清经Sephacryl S-200层析,截取相对分子质量(50~200)×103段,经SDS-PAGE电泳及Western-blot法鉴定。用提取的HSP/肽免疫小鼠后,再用低剂量CTX及IL-12治疗(强化疫苗),观察无瘤生存率、抑瘤生长率、抑制转移率和存活期。用流式细胞仪,ELISPOT及乳酸脱氢酶等方法检测免疫功能的变化。结果:HSP疫苗与IL-12和CTX联合治疗小鼠S-180肉瘤,80.0%肿瘤完全消退,且100.0%抑制了肺部转移,达长期生存,而对照组全部在40d内死亡。检测表明HSP/肽疫苗形成了免疫预存,从而使IL-12和CTX发挥了抗瘤作用。结论:HSP/肽与IL-12和CTX联合治疗诱发了机体细胞免疫功能,产生强大的抗瘤作用,可能具有临床应用前景。

关 键 词:肉瘤  免疫疗法  热休克蛋白类  白介素-12
文章编号:1673-5269(2007)06-0415-03
收稿时间:2006-08-10
修稿时间:2006-11-21

Therapeutic effects of combination mixed HSP vaccine with interleukin-12 in mice sarcoma
CUI Xue-mei,YUAN Mei,SONG Ge,SUI Xiang,ZHAO Bin,LU Shi-bi. Therapeutic effects of combination mixed HSP vaccine with interleukin-12 in mice sarcoma[J]. Chinese Journal of Cancer Prevention and Treatment, 2007, 14(6): 415-417
Authors:CUI Xue-mei  YUAN Mei  SONG Ge  SUI Xiang  ZHAO Bin  LU Shi-bi
Abstract:OBJECTIVE:To investigate the effects of enhanced mixed heat shock protein/peptides for immunotherapy of mouse sarcoma. METHODS: Mixed heat shock protein/peptides were extracted from mouse sarcoma cell line S-180 by chromatography with Saphacryl S-200,identified by SDA-PAGE and Western-blot, and S-180 was transplanted into BALB/C mice, then the mice were immunized by mixed heat shock protein/peptides, then treated with low dose CTX, and IL-12. The tumor regression and long time survival,tumor growth inhibition rates and tumor metastasis were examined. The sub-group of T lymphocyte was examined by FACS and ELISPOT assay. RESULTS: Mice immunized by enhanced vaccine(mixed heat shock protein/peptides/peptides and CTX, IL-12) had the best protected results. The tumor regression and long time survival was 80%. Whereas, all the tumor-bearing controls died within 40 days. CONCLUSION: In this murine tumor model, low dose administration of cyclophophamide and IL-12 can enhance the immunologic and antitumor response to tumor mixed HSP/peptides vaccine, and it has a dramatic anti-tumor effect against S-180 sarcoma. The promising data have raised much hope that it could be a powerful therapeutic agent against tumor.
Keywords:sarcoma   immunotherapy   heat-shock proteins   IL-12
本文献已被 CNKI 万方数据 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号